Clinical trials: Metastatic Colorectal Cancer, completed
Metastatic Colorectal Cancer
1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.
The purpose of this study is to determinate progression free survival after 9 months of treatment.
- Trial name
- NCT00345696
- Testing
- Bevacizumab, Capecitabine, Oxaliplatine
- Where
- Spain
- Volunteers
- 32 people
- Sponsor
- Unidad Integral de Investigación en Oncología S.L.
Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
This phase II trial studies how well TAS-102, irinotecan, and bevacizumab work in treating patients with pre-treated colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery…
- Conditions
- Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Recurrent Colon Adenocarcinoma
- Trial name
- NCT04109924
- Testing
- Irinotecan, Bevacizumab, Trifluridine and Tipiracil Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Colorectal Cancer
A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).
The purpose of this study is to collect additional safety and efficacy data during treatment with trifluridine / tipiracil in patients with a pretreated metastatic colorectal cancer (mCRC).
- Trial name
- PRECONNECT (NCT03306394)
- Testing
- Trifluridine/Tipiracil hydrochloride (S95005)
- Where
- 99 sites in Australia, Belgium and 14 more
- Volunteers
- 907 people
- Sponsor
- Institut de Recherches Internationales Servier
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Solid Tumor
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor malignancies.
- Trial name
- NCT01607905
- Testing
- Selinexor, Acetaminophen
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 192 people
- Sponsor
- Karyopharm Therapeutics Inc
Colorectal Cancer, Liver Metastasis
Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets
Early-stage colorectal cancer(CRC)is localized and resectable, but 20% of the patients have metastatic disease at the time of diagnosis and 50% of all patients eventually die of the disease.
- Trial name
- NCT01632722
- Testing
- Bevacizumab, mFOLFOX, FOLFIRI
- Where
- South Korea
- Volunteers
- 79 people
- Sponsor
- Yonsei University
Colorectal Cancer
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00556413
- Testing
- cetuximab, fluorouracil, irinotecan hydrochloride
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Colorectal Cancer
Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer
The purpose of this study is to examine the safety of ABX-EGF administered as monotherapy in subjects with metastatic colorectal cancer who were previously randomized to best supportive care (BSC) in protocol 20020408 and…
- Trial name
- NCT00113776
- Testing
- ABX-EGF
- Sponsor
- Amgen
Colorectal Cancer
The Molecular Mechanism of RAS Wild-type mCRC Resistance to Anti-EGFR-antibody
Establishing the genetic map of primary and secondary resistance of Chinese wild RAS colorectal cancer received anti-EGFR treatment through tissues and peripheral blood NGS testing.
- Trial name
- NCT04466267
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Colorectal Neoplasms
Regorafenib Post-marketing Surveillance
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Regorafenib for colorectal cancer.
- Trial name
- NCT01843400
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- Japan
- Volunteers
- 1,301 people
- Sponsor
- Bayer
NSCLC, Metastatic Colorectal Carcinoma
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
The primary goal of this trial is to assess clinical response to nivolumab and pixatimod, and, nivolumab, pixatimod and cyclophosphamide in three separate patient cohorts.
- Conditions
- NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma
- Trial name
- NCT05061017
- Testing
- Pixatimod, Nivolumab, Cyclophosphamide (low dose)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Diwakar Davar
Colorectal Cancer, Refractory Colorectal Cancer
Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study
Fruquintinib is an oral tyrosine kinase inhibitor (TKI), which improves progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC).
- Conditions
- Colorectal Cancer, Refractory Colorectal Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT06202417
- Testing
- Fruquintinib
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Fudan University
Colon Cancer, Rectal Cancer
Clinical and Translational Study of STA-9090
The purpose of this study is to find out what effects, good and/or bad STA-9090 has on colorectal cancer. This is a phase II trial which tests both how well the drug works in fighting your cancer as well as any possible side…
- Trial name
- NCT01111838
- Testing
- STA-9090
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Colorectal Cancer
Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors
Curcumin is an extract of the tumeric root that has been shown to have anti-tumor properties in laboratory studies. Curcumin, and its parent spice, turmeric (curcuma longa), are the 4th most commonly purchased dietary supplement…
- Trial name
- NCT01859858
- Testing
- curcumin, Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Metastatic Colorectal Cancer, MSI
Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer
Immune chekpoints (ICI) are evaluated in many digestive cancers. Certain types of cancer appear to be rather refractory to ICI such as colorectal cancers (CRC).
- Trial name
- SAMCO (NCT03186326)
- Testing
- FOLFOX regimen, FOLFIRI Protocol, Avelumab
- Where
- 120 sites in France
- Volunteers
- 132 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Anal Cancer, Rectal Cancer
A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal
This is a single arm Phase 2 study. Stage 1 and 2 of the study are monotherapy evaluations of ADXS11-001 in 31 and 24 participants, respectively with persistent/recurrent, loco-regional or metastatic squamous cell carcinoma…
- Trial name
- NCT02399813
- Testing
- Axalimogene filolisbac
- Where
- 10 sites in United States
- Volunteers
- 36 people
- Sponsor
- Advaxis, Inc.
Colorectal Cancer
Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)
PURPOSE: This randomized phase III trial is studying maintenance therapy with bevacizumab alone after an induction therapy combining bevacizumab+chemotherapy to see how well they work compared to maintenance therapy with…
- Trial name
- DREAM (NCT00265824)
- Testing
- bevacizumab, bevacizumab, erlotinib
- Where
- 47 sites in Austria, Canada and 1 more
- Volunteers
- 700 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Metastatic Colorectal Cancer
Study of Circulating Markers in Serum of Patients Treated for Metastatic Colorectal Cancer
The primary purpose of the study is to confirm the results of previous study about the usefulness of the serum Carcinoembryonic antigen (CEA) kinetic for chemotherapy monitoring in patients with unresectable metastasis of…
- Trial name
- Coca-Colon (NCT01212510)
- Testing
- Blood sampling
- Where
- 4 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Rouen
Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
A clinical trial to assess the safety and efficacy of genetically-engineered, neoantigen-specific Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune checkpoint CISH has been inhibited using CRISPR gene editing…
- Conditions
- Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract, Cancer, Gastrointestinal
- Trial name
- NCT04426669
- Testing
- Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Intima Bioscience, Inc.
Metastatic Colorectal Cancer
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone
This clinical trial will be performed in previously untreated patients with metastatic colorectal cancer. The study will evaluate the safety, tolerability and efficacy of the study drug, CT-011, in combination with FOLFOX…
- Trial name
- NCT00890305
- Testing
- CT-011, FOLFOX
- Where
- 31 sites in United States, Bulgaria and 4 more
- Volunteers
- 171 people
- Sponsor
- Medivation, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.